BioCryst Pharmaceuticals, Inc.
BCRX$9.30
+$0.23 (2.54%)+2.54%
ClosedLoading chart...
IndexN/A
Market Cap2.36B
Enterprise Value1.99B
Income$0.00B
Sales$0.15B
EmployeesN/A
P/E-6.20
P/S1.87
P/B-13.74
P/C5.00
EV/EBITDA5.71
EV/SalesN/A
EPS (ttm)-1.50
EarningsN/A
Gross Margin97.82%
Oper. Margin38.98%
Profit Margin30.16%
Volume4.04M
Shs Outstand0.25B
Change2.54%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M | $48.84M | $20.65M | $25.19M |
| Cost of Revenue | $12.48M | $4.66M | $6.59M | $7.26M | $1.68M | $4.10M | $471.00K | $1.70M |
| Gross Profit | $438.23M | $326.75M | $264.23M | $149.91M | $16.14M | $44.73M | $20.18M | $23.48M |
| Gross Margin | 97.23% | 98.59% | 97.57% | 95.38% | 90.59% | 91.60% | 97.72% | 93.24% |
| Operating Expenses | $440.77M | $430.46M | $412.67M | $327.63M | $190.89M | $144.19M | $114.40M | $80.89M |
| Operating Income | $-2.54M | $-103.71M | $-148.44M | $-177.72M | $-174.76M | $-99.45M | $-94.22M | $-57.41M |
| Operating Margin | -0.56% | -31.29% | -54.81% | -113.08% | -981.12% | -203.66% | -456.20% | -227.95% |
| Net Income | $-88.88M | $-226.54M | $-247.12M | $-184.06M | $-182.81M | $-108.90M | $-101.25M | $-65.78M |
| Net Margin | -19.72% | -68.36% | -91.24% | -117.11% | -1026.35% | -222.99% | -490.25% | -261.18% |
| EPS (Basic) | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.94 | $-0.98 | $-0.78 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $490.42M | $516.96M | $550.00M | $588.15M | $334.71M | $175.28M | $146.84M | $178.26M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $966.35M | $972.49M | $844.60M | $695.14M | $353.98M | $137.03M | $97.61M | $94.49M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $-475.93M | $-455.53M | $-294.60M | $-106.99M | $-19.26M | $38.25M | $-731.97M | $-631.84M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $-475.93M | $-455.53M | $-294.60M | $-106.99M | $-19.26M | $38.25M | $-731.97M | $-631.84M |
| Total Liabilities & Stockholders Equity | $490.42M | $516.96M | $550.00M | $588.15M | $334.71M | $175.28M | $146.84M | $178.26M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-88.88M | $-226.54M | $-247.12M | $-184.06M | $-182.81M | $-108.90M | $-101.25M | $-65.78M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-52.02M | $-95.14M | $-161.85M | $-142.16M | $-137.22M | $-89.58M | $-92.56M | $-41.14M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcriptseekingalpha.com BioCryst Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimateszacks.com BioCryst Reports Second Quarter 2026 Financial Resultsglobenewswire.com ADAR1 Capital Management LLC Has $1 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRXdefenseworld.net BioCryst to Report Second Quarter 2026 Financial Results on August 5globenewswire.com BioCryst Appoints David W. Jenkins as Chief Scientific Officerglobenewswire.com Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Betzacks.com
Show 12 more stories
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?zacks.com BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com BioCryst scraps internal drug discovery programs, leans on partnerships to cut costsreuters.com BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facilityglobenewswire.com BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Upseekingalpha.com BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meetingglobenewswire.com BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meetingglobenewswire.com BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026globenewswire.com BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earningsbenzinga.com BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcriptseekingalpha.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Discover more
You may be interested in